Abeona Therapeutics Inc.2024财年第二财季实现净利润7.41百万美元，同比增加144.50%

自选股智能写手08-17

8月17日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2024财年第二财季净利润为7.41百万美元，同比增加144.50%；其中营业收入为0.00美元，每股基本收益为0.19美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债60.76百万美元，其中短期债务4.01百万美元，资产负债比为0.03，流动比率为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460249735?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460249735","market":"us","top_or_hot":-1,"title":"Abeona Therapeutics Inc.2024财年第二财季实现净利润7.41百万美元，同比增加144.50%","media":"自选股智能写手","content":"<div>\n<p>8月17日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2024财年第二财季净利润为7.41百万美元，同比增加144.50%；其中营业收入为0.00美元，每股基本收益为0.19美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债60.76百万美元，其中短期债务4.01百万美元，资产负债比为0.03，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005589f31b12a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abeona Therapeutics Inc.2024财年第二财季实现净利润7.41百万美元，同比增加144.50%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbeona Therapeutics Inc.2024财年第二财季实现净利润7.41百万美元，同比增加144.50%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005589f31b12a&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月17日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2024财年第二财季净利润为7.41百万美元，同比增加144.50%；其中营业收入为0.00美元，每股基本收益为0.19美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债60.76百万美元，其中短期债务4.01百万美元，资产负债比为0.03，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005589f31b12a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABEO","symbol_name":"Abeona Therapeutics Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005589f31b12a&s=b","article_id":"2460249735","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005589f31b12a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460249735","pubTimestamp":1723824037,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月17日，Abeona Therapeutics Inc.公布财报，公告显示公司2024财年第二财季净利润为7.41百万美元，同比增加144.50%；其中营业收入为0.00美元，每股基本收益为0.19美元。机构评级：截至2024年8月17日，当前有6家机构对Abeona Therapeutics Inc.目标价做出预测，其中目标均价为15.92美元，其中最低目标价为7.50美元，最高目标价为21.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ABEO":"Abeona Therapeutics Inc","LENZ":"Therapeutics","ABEOW":"Abeona Therapeutics Inc."},"translate_title":"Abeona Therapeutics Inc. achieved net profit of US $7.41 million in the second fiscal quarter of fiscal year 2024, a year-on-year increase of 144.50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABEO":1,"ABEOW":1,"LENZ":1},"content_text":"8月17日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2024财年第二财季净利润为7.41百万美元，同比增加144.50%；其中营业收入为0.00美元，每股基本收益为0.19美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债60.76百万美元，其中短期债务4.01百万美元，资产负债比为0.03，流动比率为0.08。机构评级：截至2024年8月17日，当前有6家机构对Abeona Therapeutics Inc.目标价做出预测，其中目标均价为15.92美元，其中最低目标价为7.50美元，最高目标价为21.00美元。公司简介：Abeona Therapeutics Inc是一家临床阶段的生物制药公司。 该公司专注于开发威胁生命的罕见遗传疾病的基因疗法和基于血浆的产品。其临床项目包括 pz-cel，一种目前正在开发中用于治疗隐性遗传性表皮水疱性松解症（RDEB）的自体工程细胞疗法。该公司的开发组合还包括基于腺相关病毒（AAV）的基因治疗，旨在利用新颖的AIM治疗未满足医学需求的眼科疾病。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460249735"}